Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samrat Khanna

Pulmonary Disease Kankakee, IL Medical Doctor

NPI 1053629881 CMS profile 962903

500 N Wall St Ste C400, Kankakee, IL 60901

Open in the dashboard

General payments

$20,762

690 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samrat Khanna of Kankakee, IL is reported in the CMS Open Payments database as having received $20,762 across 690 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,087 93
2024 General $10,303 123
2023 General $1,791 101
2022 General $2,006 93
2021 General $1,812 98
2020 General $743 48
2019 General $2,020 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samrat Khanna
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Samrat Khanna were reported at $2,087. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Samrat Khanna Pulmonary Disease median Middle half National median
2019 $2,020 $377 $109–$1,340 $163
2020 $743 $230 $56–$907 $114
2021 $1,812 $269 $68–$1,072 $132
2022 $2,006 $390 $100–$1,457 $149
2023 $1,791 $419 $114–$1,659 $160
2024 $10,303 $476 $123–$1,818 $164
2025 $2,087 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $7,881 11 payments
  2. GlaxoSmithKline, LLC. $2,464 182 payments
  3. AstraZeneca Pharmaceuticals LP $1,987 103 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,147 49 payments
  5. Jazz Pharmaceuticals Inc. $830 21 payments
  6. Mylan Specialty L.P. $648 39 payments
  7. Regeneron Healthcare Solutions, Inc. $621 25 payments
  8. United Therapeutics Corporation $576 22 payments
  9. Electromed, Inc. $469 48 payments
  10. Mallinckrodt Hospital Products Inc. $372 15 payments
  11. Other $3,768 175 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,758 678 payments
  2. Education $7,268 7 payments
  3. Travel and Lodging $736 5 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $7,881 11 payments
  2. TRELEGY ELLIPTA $1,274 96 payments
  3. NUCALA $766 49 payments
  4. FASENRA $648 23 payments
  5. BREZTRI $585 25 payments
  6. XYWAV $577 16 payments
  7. DUPIXENT $499 21 payments
  8. TEZSPIRE $456 18 payments
  9. SMARTVEST $411 41 payments
  10. YUPELRI $409 23 payments
  11. Other $8,861 456 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,462

Median for Internal Medicine: 777

Drug cost

$682,693

Median for Internal Medicine: $73,373

Branded share of claims

67.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 417 $337,653
Breo Ellipta Fluticasone/Vilanterol Brand 152 $66,545
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 62 $49,256
Spiriva Respimat Tiotropium Bromide Brand 51 $30,124
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 50 $27,361
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 33 $25,939
Advair Hfa Fluticasone Propion/Salmeterol Brand 48 $19,141
Eliquis Apixaban Brand 21 $16,065
Symbicort Budesonide/Formoterol Fumarate Brand 38 $15,337
Spiriva Handihaler Tiotropium Bromide Brand 12 $15,009

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$172,964

Medicare's payments for the services billed

Medicare patients

911

Average age 73

Services billed

2,227

457 women, 454 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Arthritis 51%
COPD 43%
Heart failure 39%
Diabetes 37%
Chronic kidney disease 37%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
$282 — —
DUPIXENT
$243 — —
FASENRA
$156 — —
JARDIANCE
$125 — —
TRELEGY ELLIPTA
$122 417 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

690 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record